25 318

Cited 38 times in

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.

Authors
Lee, HW; Han, JH; Kim, JH; Lee, MH; Jeong, SH; Kang, SY; Choi, JH; Oh, YT; Park, KJ; Hwang, SC; Sheen, SS; Lim, HY
Citation
Lung cancer (Amsterdam, Netherlands), 59(1):95-104, 2008
Journal Title
Lung cancer (Amsterdam, Netherlands)
ISSN
0169-50021872-8332
Abstract
BACKGROUND: Alterations in apoptosis-related proteins and DNA damage repair proteins are associated with resistance to chemotherapy or radiotherapy, which is the most important cause of treatment failure in small cell lung cancer (SCLC). PATIENTS AND METHODS: Pretreatment tumor biopsy specimens from 77 patients with SCLC (limited stage: 40, extensive stage: 37) were analyzed for p53, bcl-2, bax and ERCC1 expression by immunohistochemistry. All patients were treated with platinum-based doublets. The most commonly used regimen was etoposide/cisplatin (50 patients). In patients with limited stage SCLC, thoracic irradiation was performed either concurrently with chemotherapy or sequentially. RESULTS: High expression of p53, bcl-2, bax and ERCC1 was observed in 40 (52%), 72 (94%), 38 (49%) and 13 (17%) patients, respectively. High expression of ERCC1 was associated with poor OS (1-year, 23% vs. 53%; p=0.026). When grouped according to stage, a significant correlation between high expression of ERCC1 and poor outcome was observed only in patients with limited stage SCLC (p=0.017). High expression of p53, bcl-2 and bax was not correlated with patient outcome. Multivariate analysis showed that extensive stage (p=0.006) and male gender (p=0.009) were independent predictors of poor OS, while high expression of ERCC1 failed to reach statistical significance despite a trend (p=0.057). In limited stage patients, high expression of ERCC1 was an independent prognostic factor for poor OS (p=0.046), along with male gender (p=0.033). CONCLUSIONS: High expression of ERCC1 protein may be a useful predictor of poor outcome in SCLC patients treated with chemotherapy with or without radiotherapy, especially in limited stage SCLC.
MeSH terms
AdultAgedCarcinoma, Small Cell/chemistry*Carcinoma, Small Cell/mortalityDNA-Binding Proteins/analysis*Endonucleases/analysis*FemaleHumansImmunohistochemistryLung Neoplasms/chemistry*Lung Neoplasms/mortalityMaleMiddle AgedProto-Oncogene Proteins c-bcl-2/analysisTumor Suppressor Protein p53/analysisbcl-2-Associated X Protein/analysis
DOI
10.1016/j.lungcan.2007.07.023
PMID
17889401
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Science
AJOU Authors
이현우한재호김장희정성현강석윤최진혁오영택박광주황성철신승수
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse